Fate Therapeutics Inc. (FATE) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Fate Therapeutics Inc. (FATE)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.25

-0.04 (-3.10%)

At close: Jan 14, 2025, 3:59 PM

1.27

1.20%

Pre-market Jan 15, 2025, 04:03 AM EST

undefined% (undefined)

Bid	1.26
Market Cap	142.94M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.64
PE Ratio (ttm)	-0.77
Forward PE	n/a
Analyst	Hold

Ask	1.28
Volume	4,192,838
Avg. Volume (20D)	3,151,672
Open	1.31
Previous Close	1.29
Day's Range	1.04 - 1.31
52-Week Range	1.04 - 8.83
Beta	undefined

About FATE

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat mul...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 1, 2013

Employees 181

Stock Exchange NASDAQ

Ticker Symbol FATE

Website https://www.fatetherapeutics.com

Analyst Forecast

According to 10 analyst ratings, the average rating for FATE stock is "Hold." The 12-month stock price forecast is $6, which is an increase of 378.09% from the latest price.

Buy 30.00%

Hold 50.00%

Sell 10.00%

Stock Forecasts

Next Earnings Release

Fate Therapeutics Inc. is scheduled to release its earnings on Feb 24, 2025, during market hours.
Analysts project revenue of $1.12M, reflecting a -33.17% YoY shrinking and earnings per share of -0.44, making a -2.22% decrease YoY.

Why Price Moved

1 month ago · Source

+2.64%

Fate Therapeutics shares are trading higher after ... Unlock content with Pro Subscription

1 month ago · Source

+12.38%

Fate Therapeutics shares are trading higher after the company presented 6-month follow-up data on the first patient treated in its Phase 1 Autoimmunity study.

News

1 month ago · zacks.com

Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue?

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?

1 month ago · seekingalpha.com

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options

Fate Therapeutics, Inc. reported positive phase 1 data for FT819 in treating moderate-to-severe Systemic Lupus Erythematosus, showing remission in one patient with fludarabine-free conditioning. A sec...

1 month ago · zacks.com

FATE Presents Encourgaing Data From Lupus Study, Stock Gains

Fate Therapeutics presents promising data on FT819 showing the first patient treated experienced a favorable clinical experience, achieved drug-free clinical remission, and continues on-study.

2 months ago · zacks.com

FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus

FATE reports a narrower-than-expected loss on higher revenues for the third quarter of 2024. The company's innovative pipeline is in focus.

2 months ago · zacks.com

Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.46 per share a year ago.